Síndrome de Sjögren
| Agente | Año | Tipo de estudio | Pacientes (n) | TR (n) | Casos adversos | Recaída | Muertes |
|---|---|---|---|---|---|---|---|
| Infliximab | A |
54 |
9 |
6 |
0 |
0 |
|
| Total | 54 |
9 |
6 |
0 |
0 |
||
| % | 16,6666667 |
11,1111111 |
|||||
| Infliximab | C |
10 |
10 |
6 |
0 |
0 |
|
| Total | 10 |
10 |
6 |
0 |
0 |
||
| % | 100 |
60 |
|||||
| Infliximab | D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 1 |
1 |
0 |
0 |
0 |
||
| % | 100 |
0 |
|||||
| Etanercept | A |
14 |
5 |
2 |
0 |
0 |
|
| Total | 14 |
5 |
2 |
0 |
0 |
||
| % | 35,7142857 |
14,2857143 |
|||||
C |
15 |
4 |
1 |
0 |
0 |
||
| Total | 15 |
4 |
1 |
0 |
0 |
||
| % | 26,6666667 |
6,66666667 |
|||||
| Rituximab | 2005 |
C |
6 |
5 |
2 |
0 |
0 |
2006 |
C |
15 |
14 |
6 |
1 |
0 |
|
2006 |
C |
16 |
13 |
3 |
5 |
0 |
|
2006 |
C |
6 |
6 |
2 |
0 |
0 |
|
2007 |
C |
15 |
15 |
2 |
0 |
0 |
|
| Total | 58 |
53 |
15 |
6 |
0 |
||
| % | 91,3793103 |
25,862069 |
|||||
| Rituximab | 2002 |
D |
1 |
1 |
0 |
0 |
0 |
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
1 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
2 |
2 |
1 |
2 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 11 |
11 |
1 |
3 |
0 |
||
| % | 100 |
9,09090909 |
|||||
| Epratuzumab | B |
16 |
7 |
10 |
0 |
0 |
|